[ PRINT ] [ Printing FAQ ] About OncoLink Editorial Board Sponsors Help See Today's OncoTip Usage Statistics Virtual Classroom Abramson Family Cancer Research Institute "Confronting Cancer Through Art" is an exhibition by people whose lives have been touched by cancer. This week we are featuring artwork by: Jacqueline Kniewasser Pontypool, Ontario Visit the Children's Art Gallery This week's artwork was donated by a pediatric cancer patient who received treatment for cancer at The Children's Hospital of Philadelphia.

Breast Cancer: Treatment Options - Drugs: Taxol and Tamoxifen Last Revision Date: Sunday, 14-Feb-1999 13:54:27 EST Copyright © 1994-1999, The Trustees of the University of Pennsylvania WCN News: Endometrial cystic atrophy common in subset of postmenopausal women on tamoxifen- Endometrial cystic atrophy is relatively common in tamoxifen-treated women with endometrial thickening, but may not be detected at curettage-hysteroscopy. OncoLink: Anticipated New Synthesis of Taxol May Generate Beneficial Analogs OncoLink@ASCO98: New Taxol® Regimen Significantly Increases a Woman's Chances for Breast Cancer Cure - Study Results Show Significant Reduction in Risk of Death and Recurrence of Cancer. OncoLink@ASCO98: Tamoxifen Reduces Breast Cancer Incidence by 45% in Women at High Risk of Developing the Disease OncoLink@ASCO98: Taxol Use Results in Significant Survival Benefit When used in Adjuvant Setting for Node-Positive Breast Cancer Patients OncoLink@ASCO: New Study Finds that Effectiveness of Autologous Blood and Bone Marrow Transplants not Impacted by Age OncoLink@ASCO: Randomized Trial Of 2 Vs. 5 Years Of Adjuvant Tamoxifen In Postmenopausal Women With Early-Stage Breast Cancer OncoLink@ASCO: Reduction of Skeletal Morbidity and Prevention of Bone Metastases with Oral Clodronate in Women with Recurrent Breast Cancer in the Absence of Skeletal Metastases OncoLink: Debate on the Ethics of the Tamoxifen Trial OncoLink FAQ: Flax Seed and Tamoxifen - An OncoLink reader has questions about Tamoxifen and flax seed. OncoLink FAQ: Tamoxifen Therapy for Estrogen Receptor Negative Breast Cancer OncoLink FAQ: Tamoxifen Withdrawal - An OncoLink reader is concerned about signs of "Tamoxifen withdrawal." OncoLink: FDA Advisory Committee Reevaluates Tamoxifen Prevention Trial OncoLink Journal Scan: "Prevention of Breast Cancer With Tamoxifen: Preliminary Findings From The Italian Randomised Trial Among Hysterectomised Women" - Lancet 1998; volume 352: pages 93 - 97 OncoLink: MEDLINE Search of Tamoxifen and Depression OncoLink: MEDLINE Search of Tamoxifen Side-Effects OncoLink: The New Taxoid -- Docetaxel OncoLink: Special Report: Tamoxifen and Risk of Uterine Cancer OncoLink: TAMOXIFEN WARNING: Increased Risk of Cancer of the Uterus OncoLink: Taxol Approved for Breast Cancer SGO: Gynecologic Oncologists' Study Questions Whether Shortened Drug-Delivery Schedule Threatens Cancer Patient' Quality of Life (8/7/96) - A study in the journal Gynecologic Oncology, suggests that shortening the infusion time of paclitaxel (taxol) when given with cisplatin chemotherapy increases the incidence of peripheral nerve damage.

GENERAL DISCLAIMER OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

For further information, consult the Editors at: editors@oncolink.upenn.edu